title: State of the art in intravesical therapy for lower urinary tract symptoms.
abstract: Intravesical therapy is the routine first-line treatment for effectively delaying or preventing the recurrence of bladder cancer. This route of drug administration has also shown tremendous promise in the treatment of interstitial cystitis/painful bladder syndrome (IC/PBS) and potentially overactive bladder to justify investments for further improvements. This review takes a bird's eye view into the current status of intravesical therapy, with emphasis on liposomal nanoparticles, in diseases associated with lower urinary tract symptoms (LUTS). Ongoing efforts to advance the field of intravesical drug delivery include development of sustained-release drug implants and efforts to improve delivery of biotechnological products including large protein acting as neurotoxins and small interfering RNAs.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Kaufman
authors.forename: Vikas
authors.initials: V
authors.lastname: Tyagi
authors.forename: Michele
authors.initials: M
authors.lastname: Anthony
authors.forename: Michael B
authors.initials: MB
authors.lastname: Chancellor
authors.forename: Pradeep
authors.initials: P
authors.lastname: Tyagi